22.06.2015 • NewsPeopleManaging DirectorDirector

Christophe Villain appointed Managing Director of Arkema’s Fluorogas business

Christophe Villain is being appointed Managing Director of the Fluorogas...
Christophe Villain is being appointed Managing Director of the Fluorogas business unit of French chemical manufacturer Arkema effective 1st July 2015.

Christophe Villain is being appointed Managing Director of the Fluorogas business unit of French chemical manufacturer Arkema effective 1st July 2015.
Villain is a graduate of Ecole Nationale Supérieure de Chimie in Paris. He began his career at Elf Atochem in 1987 as Polypropylene Development Engineer within the Appryl subsidiary. In 1990, he joined General Electric Plastics to head marketing in the automotive sector. In 1996, he became Head of Elf Atochem’s Polystyrene Department, and in 2001 Head of Atofina’s global Bleaching Department. In 2003, he was appointed Managing Director of Arkema’s Urea Formaldehyde Resins business unit. From 2006 to 2011, he was Managing Director of CECA, and since 2011 had been Managing Director of the PMMA (Altuglas International) business unit.

 

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
12.12.2024 • NewsPharma

Austria: A Hotspot for Life Sciences

An Attractive and Highly Sought-after Business Location

The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.